Complement C1 Complex Activity Assay

Creative Biolabs offers customized complement C1 complex activity assay services to support discovery, characterization, optimization, and validation programs involving classical pathway modulation. Our assay platforms are designed to evaluate the activity of the intact C1 complex, the functional integrity of C1q-mediated recognition, C1r/C1s protease activation, and other key events.

Submit Your Request Now

Download our service brochure

Inquiry

Overview of the Complement C1 Complex

The C1 complex is the first functional unit of the classical complement pathway. It integrates a recognition module, C1q, with a protease module composed of two C1r and two C1s molecules. C1q recognizes specific/activating molecular structures, most commonly clustered Fc regions on antigen-bound IgM or IgG, but it may also interact with other classical pathway activators such as apoptotic cell-associated structures, pentraxins, pathogen-associated surfaces, and immune complexes. Once C1q binds to an activating surface, conformational changes promote C1r activation, followed by C1s activation. Activated C1s then cleaves C4 and C2, creating the C4b2a classical pathway C3 convertase and initiating downstream complement amplification.

This early activation step is biologically important because small changes in C1 recognition or protease activity can produce large differences in downstream complement outcomes. Therefore, a robust C1 complex activity assay should not be limited to a single endpoint. It should be able to distinguish recognition, activation, cleavage, deposition, amplification, and inhibition mechanisms.

Creative Biolabs develops customized C1 complex activity assays around this principle. We can help clients ask precise questions such as:

Does a candidate antibody recruit functional C1?
Does an inhibitor suppress C1 complex activation upstream of C4 cleavage?
Does a patient sample contain abnormal classical pathway activity?
Does a biologic trigger unwanted complement activation?
Does an engineered Fc modification improve or reduce C1-dependent function?
Does a disease-associated variant affect C1 assembly, C1r/C1s activation, or downstream classical pathway signaling?

Great Minds Choose Creative Biolabs

Partner with Us

Creative Biolabs' Complement C1 Complex Activity Assay Platform

Creative Biolabs provides flexible C1 complex activity assay solutions that can be configured according to project objectives. Our platform can support early exploratory studies, lead candidate ranking, potency testing, mechanism-of-action analysis, cross-species comparability, inhibitor profiling, disease sample analysis, and assay development for long-term research use.

Purified C1 Complex Activity Assays

Purified-protein assays are useful when the goal is to evaluate direct effects on C1 complex activity without the complexity of whole serum. These formats may use purified human or species-specific C1 complex, recombinant or purified C1 components, defined immune-complex activators, C4/C2 substrates, and biochemical detection readouts. They can help determine whether a test article directly blocks C1 activation, C1r/C1s protease function, or C4/C2 cleavage.

Serum-Based Classical Pathway Assays

Serum-based assays preserve the physiological context of complement proteins, regulators, inhibitors, and downstream pathway components. Creative Biolabs can design serum-based C1 activity assays using normal human serum, complement-depleted serum, patient-derived samples, animal serum, reconstituted systems, or serum spiked with test molecules.

Cell-Based C1 Complex Activity Assays

Cell-based assays provide a biologically relevant surface for complement activation and can connect early C1 complex activity with downstream cellular outcomes. Depending on the model, target cells may be coated with antigen-specific antibodies, immune complexes, patient antibodies, or customized ligands. C1 activity can then be evaluated through deposition of C1q, C4b, C3b, iC3b, C5b-9, cell lysis, cell viability changes, opsonization, or imaging-based complement localization.

Immune-Complex-Triggered C1 Activation Assays

Creative Biolabs can develop immune-complex-triggered assay systems to evaluate how soluble or surface-bound immune complexes activate C1. These formats can be used to model autoimmune disease mechanisms, evaluate immune-complex clearance biology, compare antibody isotypes or subclasses, test Fc-engineered molecules, and study inhibitors that block immune-complex-induced complement activation.

C1 Inhibition and Potency Assays

For drug discovery programs targeting the classical pathway, Creative Biolabs can establish C1 complex inhibition assays to assess potency, selectivity, and mechanism. Test articles may include monoclonal antibodies, antibody fragments, engineered proteins, peptides, small molecules, RNA-based candidates, C1 inhibitor preparations, fusion proteins, nanoparticles, or other biologics.

Discuss Your Needs

Assay Formats We Can Support

ELISA-Based C1 Complex Activity Assays

For screening, candidate comparison, sample profiling, and quantitative endpoint measurement

Flow Cytometry-Based Assays

For analysis of C1q binding, C4b deposition, C3b/iC3b deposition, C5b-9 formation

Biochemical Protease Activity Assays

For inhibitor screening, enzyme kinetics, specificity assessment, and mechanistic studies

Hemolysis-Based Functional Assays

An integrated functional readout of classical pathway activity

Workflow of Complement C1 Complex Activity Assay

Complement C1 complex assay. (Creative Biolabs Original) Fig. 1 The workflow of C1 complex ELISA (upper) and hemolytic assay (lower).

Design Your Workflow

Key Readouts Available for C1 Complex Activity Testing

Creative Biolabs can build a customized readout panel based on the specific biological question. A C1 complex activity project may include one or multiple endpoints.

C1q Binding, C1r and C1s Activation

C1q binding assays evaluate whether test materials recruit C1q to immune complexes, antibody-coated surfaces, target cells, or other activating structures.
Assays that monitor C1r/C1s activation provide more direct information than C1q binding alone.

C4 Cleavage and C4b/C4d Generation, C2 Cleavage and Classical C3 Convertase Formation, C3 Fragment Deposition

C4 cleavage is one of the most important functional consequences of C1 complex activation.
C2 cleavage is required for formation of the classical pathway C3 convertase.
C3b or iC3b deposition can be used as an integrated readout of classical pathway initiation and amplification.

Terminal Complement Complex Formation, Hemolysis and Cell Damage

C5b-9 deposition or soluble terminal complement complex generation as a downstream consequence of C1-dependent activation.
Classical pathway hemolysis remains a functional readout for complement activity.

Multiplex Complement Profiling

Integrate C1 complex activity testing with multiplex complement analysis.
Potential readouts include C1q, C4a, C4d, C3a, C3b/iC3b, C5a, C5b-9, Ba, Bb, factor consumption, and pathway-specific biomarkers.

Applications of Complement C1 Complex Activity Assays

Application	Description
Therapeutic Antibody Development	C1 complex activity testing is highly relevant for therapeutic antibodies. Antibody-mediated complement activation depends on antigen density, antibody subclass, Fc structure, Fc clustering, target-cell surface properties, and local complement regulation. Creative Biolabs can evaluate whether antibody candidates recruit C1q, activate C1, induce C4/C3 deposition, form terminal complement complexes, or mediate complement-dependent cytotoxicity.
Complement Inhibitor Discovery	C1 complex activity assays can be used to screen and characterize inhibitors targeting C1q, C1r, C1s, C1 complex assembly, or classical pathway initiation. Creative Biolabs can design dose-response assays, pathway-selectivity panels, species cross-reactivity studies, serum matrix evaluations, and mechanism-of-action experiments. These services can help clients prioritize candidates and understand whether inhibition occurs at the recognition, activation, protease, or downstream cleavage level.
Autoimmune and Immune-Complex Disease Research	The classical pathway is closely associated with immune-complex biology. C1 complex activity assays can be used to study complement activation induced by patient-derived immune complexes, autoantibodies, disease-associated sera, or experimental immune-complex models. These assays may support research related to systemic lupus erythematosus, immune-complex vasculitis, glomerulonephritis, antibody-mediated transplant injury, autoimmune cytopenias, and other complement-associated diseases.
Biologics Safety Assessment	Biologics, nanoparticles, cell therapy products, and engineered protein constructs can activate complement under certain conditions. C1 complex activity assays can help determine whether a test material triggers classical pathway activation and whether activation is dependent on antibodies, immune complexes, aggregation, Fc-mediated recognition, or surface-associated factors. This information can support risk assessment, formulation optimization, and preclinical development.
C1-INH and Classical Pathway Regulation Studies	C1 inhibitor is a key regulator of C1r and C1s activity. Creative Biolabs can support studies evaluating C1-INH function, C1-INH replacement products, C1-INH-related inhibition, and dysregulated C1 activity. Assays can be configured to measure suppression of C1 activation, C4 cleavage, C4d generation, and downstream classical pathway activity.
Disease Biomarker and Translational Research	C1 complex activity readouts can contribute to translational research by linking serum complement function, immune-complex burden, pathway activation, and therapeutic response. Creative Biolabs can help develop fit-for-purpose assays for exploratory biomarker studies, sample stratification, pharmacodynamic monitoring, and preclinical-to-clinical assay transition planning.

Design Your Customization

Case Studies

Case 1

Quantitative Visualization of the Interaction between Complement Component C1 and Immunoglobulin G

Immunoglobulin G (IgG) adopts a modular multidomain structure that mediates antigen recognition and effector functions, such as complement-dependent cytotoxicity. IgG molecules are self-assembled into a hexameric ring on antigen-containing membranes, recruiting the complement component C1q. In order to provide deeper insights into the initial step of the complement pathway, the researchers reported a high-speed atomic force microscopy study for the quantitative visualization of the interaction between mouse IgG and the C1 complex composed of C1q, C1r, and C1s.

Complement component C1 and immunoglobulin G. (OA Literature) Fig. 2 HS-AFM observation of C1 and C1q.^1,2

References

Yanaka, Saeko, et al. "Quantitative visualization of the interaction between complement component C1 and immunoglobulin G: the effect of CH1 domain deletion." International journal of molecular sciences 23.4 (2022): 2090. https://doi.org/10.3390/ijms23042090
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"Our antibody discovery program required a detailed evaluation of classical pathway activation potential across multiple Fc-engineered antibody variants. Initial C1q binding data alone could not fully explain differences in downstream complement activity. Creative Biolabs designed a customized workflow combining C1q recruitment analysis, C4b deposition measurement, and downstream complement activation assessment."

— Senior Scientist, Therapeutic Antibody Discovery Company

"We were developing a novel inhibitor targeting early classical pathway activation and needed an assay system capable of determining both potency and mechanism of action. Creative Biolabs helped establish a multi-stage evaluation workflow that included purified C1 complex analysis, serum-based complement activation testing, and downstream C4 cleavage monitoring."

— Research Director, Complement Therapeutics Program

"Our project focused on immune-complex-mediated complement activation in disease-associated samples. A major challenge was maintaining physiological relevance while obtaining reproducible complement activation signals. Creative Biolabs helped optimize serum conditions, immune-complex stimulation parameters, and detection endpoints."

— Principal Investigator, Immunology Research Laboratory

"For our biologic candidate, understanding complement activation on target cells was critical. Creative Biolabs developed a cell-based C1 complex activity assay incorporating target-cell activation, complement deposition analysis, and downstream functional measurements. The platform helped us better understand how molecular interactions translated into cellular complement responses."

— Associate Director, Biologics Development

Frequently Asked Questions

What is the difference between C1 complex activity testing and C1q binding assays?

C1q binding assays determine whether C1q interacts with an antibody, immune complex, target cell, or molecular surface. However, C1q attachment does not always result in activation of the complete C1 complex. C1 complex activity assays evaluate downstream functional consequences after C1 recognition, such as C1r/C1s activation or C4 cleavage. Therefore, they provide additional information about whether the interaction generates meaningful classical pathway activation.

Can the assay evaluate the activity of intact C1 complex rather than individual components?

Yes. Creative Biolabs can design assays specifically for intact C1 complex activity evaluation. These assays may use purified C1 complex, serum-based complement systems, immune-complex activation models, or cell-based platforms. Testing intact C1 complex function is particularly useful when researchers need to evaluate the complete biological process involving C1q recognition, C1r activation, C1s activation, and downstream complement initiation rather than only measuring one individual protein interaction.

How long does a Complement C1 Complex Activity Assay project take?

Project timelines depend on assay complexity, sample availability, assay development requirements, and the number of requested endpoints. A standard assay using an established platform may require less development time, while customized workflows involving new activation systems, cell models, cross-species analysis, or multiplex readouts may require additional optimization. Creative Biolabs can provide a project-specific timeline after reviewing experimental objectives and requirements.

Can Creative Biolabs help design a complete classical pathway evaluation strategy?

Yes. In addition to C1 complex activity assays, Creative Biolabs provides broader complement testing solutions covering upstream activation, pathway-specific functional assays, complement deposition analysis, inhibitor evaluation, and downstream terminal pathway assessment. Our scientists can help design a staged evaluation strategy that begins with molecular characterization and progresses toward serum-based and cell-based functional validation.

How much sample is required?

Sample volume depends on assay format, number of endpoints, number of replicates, dilution series, controls, and whether repeat testing is needed. Purified-protein assays may require relatively small amounts of test article, while multi-readout serum or cell-based studies may require larger volumes. Creative Biolabs can provide a project-specific sample requirement estimate after reviewing the study design.